BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 15955857)

  • 1. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
    Grazioli L; Morana G; Kirchin MA; Schneider G
    Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine.
    Grazioli L; Morana G; Federle MP; Brancatelli G; Testoni M; Kirchin MA; Menni K; Olivetti L; Nicoli N; Procacci C
    Radiology; 2001 Dec; 221(3):731-9. PubMed ID: 11719669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
    Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
    J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
    Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
    J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal nodular hyperplasia of the liver: detection and characterization with plain and dynamic-enhanced MRI.
    Mortelé KJ; Praet M; Van Vlierberghe H; de Hemptinne B; Zou K; Ros PR
    Abdom Imaging; 2002; 27(6):700-7. PubMed ID: 12395259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging.
    Mahfouz AE; Hamm B; Taupitz M; Wolf KJ
    Radiology; 1993 Jan; 186(1):133-8. PubMed ID: 8416554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
    Pirovano G; Vanzulli A; Marti-Bonmati L; Grazioli L; Manfredi R; Greco A; Holzknecht N; Daldrup-Link HE; Rummeny E; Hamm B; Arneson V; Imperatori L; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
    Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
    AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
    Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
    AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Magnetic resonance imaging of hepatic focal lesions: dynamic contrastographic evaluation with gadolinium versus reticulo-endothelial hepato-specific contrast media].
    Di Cesare E; Cariello G; Barile A; Sabatini M; Michelini O; Erriquez D; Masciocchi C
    Radiol Med; 2000 Oct; 100(4):245-50. PubMed ID: 11155451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.
    Petersein J; Spinazzi A; Giovagnoni A; Soyer P; Terrier F; Lencioni R; Bartolozzi C; Grazioli L; Chiesa A; Manfredi R; Marano P; Van Persijn Van Meerten EL; Bloem JL; Petre C; Marchal G; Greco A; McNamara MT; Heuck A; Reiser M; Laniado M; Claussen C; Daldrup HE; Rummeny E; Kirchin MA; Pirovano G; Hamm B
    Radiology; 2000 Jun; 215(3):727-36. PubMed ID: 10831691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.
    Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R
    Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial).
    Martincich L; Faivre-Pierret M; Zechmann CM; Corcione S; van den Bosch HC; Peng WJ; Petrillo A; Siegmann KC; Heverhagen JT; Panizza P; Gehl HB; Diekmann F; Pediconi F; Ma L; Gilbert FJ; Sardanelli F; Belli P; Salvatore M; Kreitner KF; Weiss CM; Zuiani C
    Radiology; 2011 Feb; 258(2):396-408. PubMed ID: 21163915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis.
    Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
    Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.